Openbookopenbook
Openbook
IHE
+11.80 · +15.76%
$86.69 · NYSE ARCA

iShares U.S. Pharmaceuticals ETF (IHE) ETF Analysis | Health

iShares · United States
AUM:$1.1B
#– of – in Health ETFs

Educational tool only – Figures are based on historical data, holdings and expense metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Market Performance

Up 28.2% over the past year, reflecting strong price momentum.

Cost Efficiency

Ongoing charge of 0.40% — moderate cost. Consider how fees compound over long holding periods.

What is IHE?

The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents.

Performance Highlights

Returns (%)
Top Sectors (%)

Investment Breakdown

Strong Recent Performance
IHE delivered 28.2% over the past year. Historical returns only — past performance is not indicative of future results.
Moderate Cost
Expense ratio of 0.40%. Consider how fees compound over a long holding period.
Concentrated Holdings
Top 10 holdings account for 79.5% of the ETF — significant weight in a small number of names.
ETF Information
AUM$1.1B
Expense Ratio0.40%
Dividend Yield1.73%
Holdings54
Inception DateMay 2006
DomicileUnited States
DistributionNA
Index–
ProvideriShares
Beta0.70
CategoryHealth
CurrencyUSD
Portfolio Impact

How would IHE affect your portfolio?

Sign in to see exactly what adding this ETF changes — sector exposure, yield, diversification, volatility. Real numbers from your actual holdings.

Sign in
Example preview
6168
+7 points · better diversified

Chart Tools

My Portfolio

Sign in to overlay your portfolio on the chart.

Sign in
Compare Equity
Uses ISF.L (iShares FTSE 100 ETF)
Indicators

Performance Metrics

Historical returns

6M
+13.6%
1Y
+49.2%
3Y
+71.2%
5Y
+75.3%
OpenBook InsightIf you had invested £10,000 in IHE 5 years ago, it would have grown to £17,534 — a gain of £7,534.

Annual Returns

Calendar year performance

IHE delivered positive returns in 4 of the last 5 calendar years.
YearIHE
2026 YTD+22.9%
2025+31.9%
2024+6.8%
2023+1.0%
2022-4.1%
CAGR 4yr+8.1%
4/5 positive yearsAvg return: +11.7%Worst year: -4.1% (2022)

Technical Analysis Summary

Automated insights from historical price action and indicators

Technical Regime: MIXED
Trend Strength
67%
Positive
Volatility
17.9%
Low
Momentum
+5.2%
30-day change
Support Level
100.62
Key floor
Key Insights
  • Monitor key support and resistance levels as part of broader risk assessment.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.